Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Apellis Pharmaceuticals Inc shares valued at $171,175 were sold by Watson David O. on Dec 11 ’24. At $34.23 per share, Watson David O. sold 5,000 shares. The insider’s holdings dropped to 112,721 shares worth approximately $3.83 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, DAVID OSBORNE WATSON purchased 5,000 shares, netting a total of over 171,175 in proceeds.
Before that, Dunlop A. Sinclair had sold 37,000 shares from its account. In a trade valued at $1,340,597, the Director traded Apellis Pharmaceuticals Inc shares for $36.23 each. Upon closing the transaction, the insider’s holdings decreased to 37,000 shares, worth approximately $3.4 million.
As published in a research note from Goldman on December 17, 2024, Apellis Pharmaceuticals Inc [APLS] has been rated down from a Buy to a Neutral and the price target has been revised to $36. Analysts at Morgan Stanley started covering the stock with ‘”an Equal-weight”‘ outlook in a report released in late November. As of October 25, 2024, RBC Capital Mkts has initiated its “Sector perform” rating for APLS. Earlier on October 16, 2024, William Blair initiated its rating. Their recommendation was “an Outperform” for APLS stock.
Analyzing APLS Stock Performance
During the last five days, there has been a surge of approximately 0.06%. Over the course of the year, Apellis Pharmaceuticals Inc shares have dropped approximately -43.17%. Shares of the company reached a 52-week high of $73.80 on 01/09/24 and a 52-week low of $24.34 on 11/05/24. A 50-day SMA is recorded $29.91, while a 200-day SMA reached $39.36. Nevertheless, trading volume fell to 1.69 million shares from 2.33 million shares the previous day.
Support And Resistance Levels for Apellis Pharmaceuticals Inc (APLS)
According to the 24-hour chart, there is a support level at 33.26, which, if violated, would cause prices to drop to 32.51. In the upper region, resistance lies at 35.24. The next price resistance is at 36.46. RSI (Relative Strength Index) is 58.00 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.01, which suggests the price will decrease in the coming days. Percent R is at 42.93%, indicating low price movement. Stochastics %K at holding indicates that the stock is to be held.
